The authors show that higher concentrations of disease-associated microglial activation stage 2 (DAM2) markers are associated with reduced tau accumulation and slower cognitive decline in nondemented individuals at risk for developing Alzheimer’s disease, suggesting that microglial activation delays disease progression. The gene discussed is MAPT; the disease is Mental deterioration.